Goldman Sachs Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Buy
Tweet Send to a Friend
Goldman Sachs upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Neutral to Buy with a price target of $104.00 (from $78.00).Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE